Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,21 USD | +7,92% | +10,00% | -61,22% |
Vakgebied
Aantal werknemers: 11
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jacques Suzanne
CEO | Chief Executive Officer | 53 | 28-03-22 |
Founder | 79 | 01-09-15 | |
Wendy DiCicco
DFI | Director of Finance/CFO | 56 | 19-07-23 |
Miles Nunn
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-15 |
John Neylan
CTO | Chief Tech/Sci/R&D Officer | 70 | 08-11-22 |
Chief Operating Officer | - | 01-07-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Donald Williams
BRD | Director/Board Member | 65 | 01-06-16 |
Founder | 79 | 01-09-15 | |
Director/Board Member | 61 | 05-07-23 | |
Samir R. Patel
BRD | Director/Board Member | 55 | 29/11 |
Director/Board Member | 70 | 23-01-18 | |
Jacques Suzanne
CEO | Chief Executive Officer | 53 | 28-03-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 13 234 315 298 | 3 808 858 604 ( 28,78 %) | 0 | 28,78 % |
Bedrijfsgegevens
Akari Therapeutics Plc
22 Boston Wharf Road 7th Floor
02210, Boston
+44 20 8004 0270
http://www.akaritx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-61,22% | 8,88 mln. | |
-3,30% | 102 mld. | |
+1,79% | 96,84 mld. | |
-0,44% | 21,48 mld. | |
-18,35% | 20,82 mld. | |
-7,45% | 18,6 mld. | |
-40,31% | 16,81 mld. | |
-26,84% | 13,78 mld. | |
+0,59% | 13,4 mld. | |
+20,86% | 11,06 mld. |
- Beurs
- Aandelen
- Koers AKTX
- Onderneming Akari Therapeutics, Plc